Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
The Lancet. Oncology
|
July 13, 2016
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
Marina Bagnoli, Silvana Canevari, Daniela Califano, et al.
Clinical Pharmacokinetics
|
November 22, 2007
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG
Markus Joerger, Alwin D R Huitema, Dick J Richel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Sandro Pignata, Giovanni Scambia, Alessandra Bologna, et al.
Gynecologic Oncology
|
April 29, 2019
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials
Gennaro Daniele, Laura Arenare, Giovanni Scambia, et al.
Oncotarget
|
September 23, 2016
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC
Francesco Perrone, Gustavo Baldassarre, Stefano Indraccolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial
Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
The Lancet. Oncology
|
March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
The Journal of Pathology
|
November 3, 2020
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer
Davide Viotto, Francesca Russo, Ilaria Anania, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2007
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
Markus Joerger, Alwin D R Huitema, Dick J Richel, et al.
British Journal of Cancer
|
September 11, 2003
Supportive care in patients with advanced non-small-cell lung cancer
M Di Maio, F Perrone, C Gallo, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
The Lancet. Oncology
|
July 13, 2016
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
Marina Bagnoli, Silvana Canevari, Daniela Califano, et al.
Clinical Pharmacokinetics
|
November 22, 2007
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG
Markus Joerger, Alwin D R Huitema, Dick J Richel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Sandro Pignata, Giovanni Scambia, Alessandra Bologna, et al.
Gynecologic Oncology
|
April 29, 2019
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials
Gennaro Daniele, Laura Arenare, Giovanni Scambia, et al.
Oncotarget
|
September 23, 2016
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC
Francesco Perrone, Gustavo Baldassarre, Stefano Indraccolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial
Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
The Lancet. Oncology
|
March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
The Journal of Pathology
|
November 3, 2020
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer
Davide Viotto, Francesca Russo, Ilaria Anania, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2007
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
Markus Joerger, Alwin D R Huitema, Dick J Richel, et al.
British Journal of Cancer
|
September 11, 2003
Supportive care in patients with advanced non-small-cell lung cancer
M Di Maio, F Perrone, C Gallo, et al.
Page
of 6